- Stocks
- Healthcare
- NASDAQ: ALXN

Price (delayed)

$159.73

Market cap

$34.96B

P/E Ratio

36.97

Dividend/share

N/A

EPS

$4.32

Enterprise value

$35.46B

Alexion Pharmaceuticals Inc. is an American pharmaceutical company best known for its development of Soliris, a drug used to treat the rare disorders atypical hemolytic uremic syndrome and paroxysmal nocturnal

ALXN's revenue is up by 24% year-on-year and by 6% since the previous quarter

The company's gross profit rose by 23% YoY and by 5% QoQ

ALXN's price to earnings (P/E) is 98% higher than its last 4 quarters average of 18.7 but 57% lower than its 5-year quarterly average of 85.0

ALXN's net income is down by 35% year-on-year but it is up by 13% since the previous quarter

The company's quick ratio fell by 25% QoQ and by 8% YoY

The debt rose by 6% QoQ and by 2.5% YoY

What are the main financial stats of ALXN

Market
Valuations
Earnings

Shares outstanding

218.85M

Market cap

$34.96B

Enterprise value

$35.46B

Price to earnings (P/E)

36.97

Price to book (P/B)

3.16

Price to sales (P/S)

5.97

EV/EBIT

52.21

EV/EBITDA

34.62

EV/Sales

6.05

Revenue

$5.86B

EBIT

$679.1M

EBITDA

$1.02B

Free cash flow

$2.62B

Per share
Balance sheet
Liquidity

EPS

$4.32

Free cash flow per share

$11.96

Book value per share

$50.53

Revenue per share

$26.76

TBVPS

$42.86

Total assets

$17.55B

Total liabilities

$6.47B

Debt

$2.77B

Equity

$11.07B

Working capital

$3.74B

Debt to equity

0.25

Current ratio

3.81

Quick ratio

2.81

Net debt/EBITDA

0.49

Margins
Efficiency
Dividend

EBITDA margin

17.5%

Gross margin

91.2%

Net margin

16.3%

Operating margin

10%

Return on assets

5.5%

Return on equity

8.6%

Return on invested capital

8.3%

Return on capital employed

4.2%

Return on sales

11.6%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Alexion Pharmaceuticals stock price performed over time

Intraday

1.18%

1 week

1.93%

1 month

3.85%

1 year

43.38%

YTD

2.23%

QTD

2.23%

How have Alexion Pharmaceuticals's revenue and profit performed over time

Revenue

$5.86B

Gross profit

$5.35B

Operating income

$585.8M

Net income

$956.6M

Gross margin

91.2%

Net margin

16.3%

ALXN's operating margin has dropped by 71% year-on-year but it is up by 22% since the previous quarter

The operating income has plunged by 64% YoY but it has grown by 30% from the previous quarter

The net margin fell by 47% YoY but it rose by 7% QoQ

ALXN's net income is down by 35% year-on-year but it is up by 13% since the previous quarter

What is Alexion Pharmaceuticals's growth rate over time

What is Alexion Pharmaceuticals stock price valuation

P/E

36.97

P/B

3.16

P/S

5.97

EV/EBIT

52.21

EV/EBITDA

34.62

EV/Sales

6.05

ALXN's price to earnings (P/E) is 98% higher than its last 4 quarters average of 18.7 but 57% lower than its 5-year quarterly average of 85.0

The EPS has declined by 34% year-on-year but it is up by 15% since the previous quarter

ALXN's P/B is 50% above its last 4 quarters average of 2.1 and 9% above its 5-year quarterly average of 2.9

Alexion Pharmaceuticals's equity has increased by 7% YoY and by 6% from the previous quarter

ALXN's P/S is 39% above its last 4 quarters average of 4.3 but 16% below its 5-year quarterly average of 7.1

ALXN's revenue is up by 24% year-on-year and by 6% since the previous quarter

How efficient is Alexion Pharmaceuticals business performance

Alexion Pharmaceuticals's return on invested capital has shrunk by 70% YoY but it has increased by 15% QoQ

The ROS has dropped by 66% year-on-year but it is up by 20% since the previous quarter

Alexion Pharmaceuticals's ROA has decreased by 47% YoY but it has increased by 10% from the previous quarter

Alexion Pharmaceuticals's ROE has decreased by 42% YoY but it has increased by 12% from the previous quarter

What is ALXN's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for ALXN.

How did Alexion Pharmaceuticals financials performed over time

ALXN's total assets is 171% higher than its total liabilities

ALXN's total liabilities is up by 46% year-on-year and by 4.2% since the previous quarter

The company's quick ratio fell by 25% QoQ and by 8% YoY

The debt is 75% lower than the equity

Alexion Pharmaceuticals's equity has increased by 7% YoY and by 6% from the previous quarter

The debt rose by 6% QoQ and by 2.5% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.